Sign inJoin waitlistJoin the waitlist

Johnnie Orozco

Faculty Program Director · University of Washington School of Medicine

Credentials: · · · · · ·

History

University of Washington School of Medicine
Present
Hematology-Oncology Fellowship Program Associate Professor Fellowship · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
2009–2012
Internal Medicine
University of California-San Francisco
2006–2009
Bioengineering, University of Washington
University of Washington School of Medicine
2002–2006

Research

Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of…
Clinical Infectious Diseases · 2023 · 63 citations
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
Blood · 2013 · First of 13 authors · 54 citations
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
Blood · 2015 · 53 citations

Damian Green
26 papers
Ajay Gopal
21 papers
JP
John Pagel
18 papers
Brenda Sandmaier
17 papers
Brian Till
11 papers
Ryan Cassaday
11 papers
Roland Walter
9 papers
Pamela Becker
7 papers
AS
Andrei Shustov
6 papers
Anna Halpern
6 papers
EE
Elihu Estey
6 papers
Mary-Elizabeth Percival
6 papers

Grants

Combining Targeted RIT and Synergistic Novel Agent-Renewal
National Cancer Institute · R37
Contact PI · $4.7M · Fred Hutchinson Cancer Center
2020–2027
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations
National Cancer Institute · R21
Contact PI · $583.1K · Fred Hutchinson Cancer Center
2023–2025
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML
National Cancer Institute · K01
Contact PI · $845.1K · Fred Hutchinson Cancer Research Center
2015–2021

Clinical trials

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2007–2021
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Terminated · Phase 2
Fred Hutchinson Cancer Center
2003–2019
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
1999
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Principal investigator · Completed · Phase 1
Fred Hutchinson Cancer Center
1999–2010